Longitudinal associations between baseline CVR and 2 years changes in BDI-II score in participants with a BDI-II score <18 in the PREDIMED-PLUS trial at baseline. by Sandra Martín-Peláez (11353470)

Association between cardiovascular risk and a) depressive status (BDI-II ≥18) and b) BDI-II score, in the PREDIMED-PLUS trial, stratified by CVR factors, at baseline. by Sandra Martín-Peláez (11353470)

Mean of the difference between the RV-GLS value of the expert and trainees in four consecutive groups of 25 fetal heart clips. by Chantelle M. de Vet (16535257)

Mean of the difference between the LV-GLS value of the expert and trainees in four consecutive groups of 25 fetal heart clips. by Chantelle M. de Vet (16535257)

The %change in GABA level had a trend correlation with MEP amplitude in the left sensorimotor area (R = −0.43002, R2 = 0.1849, t = 1.844717, p = 0.082575). by Hiroyuki Matsuta (13250169)

Subjects:

Trial profile. by Chanel Avenant (409756)

“…Both contraceptives substantially decreased, from D0 to 25W, the total testosterone [DMPA-IM D0 0.560, 25W 0.423 nmol/L, -24.3% (p < 0.0001); NET-EN D0 0.551, 25W 0.253 nmol/L, -54.1%, (p < 0.0001)], SHBG [DMPA-IM D0 45.0, 25W 32.7 nmol/L, -29.8% (p < 0.0001); NET-EN D0 50.2, 25W 17.6 nmol/L, -65.1% (p < 0.0001)], and calculated free testosterone levels [DMPA-IM D0 6.87, 25W 5.38 pmol/L, -17.2% (p = 0.0371); NET-EN D0 6.00, 25W 3.70, -40.0% (p < 0.0001)]. …”

PPM1A is critical for proliferation of intestinal organoids. by Ruyuan Zhou (10197187)

“…A dramatic lower number of de novo crypts (D, top panel) and the decreased size of organoids (D, bottom panel) were seen in organoids from PPM1A KO mice, with roughly 50 intestine organoids each group examined. …”

Mean score of school factors by SES over years. by Benti Geleta Buli (15417868)

Decreases in muscle size, muscle force, and TB mass in 3-mo Lmna^HSA-cko mice. by Lei Xiong (334812)

Ivermectin significantly decreases <i>L</i>. <i>loa</i> mf in BALB/c mice. by Rene Bilingwe Ayiseh (6900296)

Effects of <i>trans ε</i>-viniferin at 10 mg/kg on amyloid deposits and neuroinflammation in cortex. by Martial Caillaud (6383672)

Effects of <i>trans ε</i>-viniferin at 10 mg/kg on amyloid deposits and neuroinflammation in hippocampus. by Martial Caillaud (6383672)

Discrimination performance deteriorated as the safe-to-conditioned ΔF decreased. by Chi Chen (67021)

Boron Leaching Decreases withIncreases on Soil pH by Alessandra Aparecida de Sá (12700698)

“…The experiment was carried out in the laboratory in 2012, and treatments consisted of a factorial combination of two rates of liming (without and with lime to raise the soil pH to 6.0) and five rates of B (0, 10, 20, 50 and 100 mg kg-1, as boric acid). …”

SARS-CoV-2 induced lung inflammation is increased with IL-10 blockade and decreased with IFNγ blockade. by Christine E. Nelson (18946410)

Heart specific RNase Z variants show a mild decrease in longevity and locomotor response. by Ekaterina Migunova (15909887)

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Combination treatments increased p53 and decreased c-Myc levels in U-87MG and U-251MG cells more than did single treatments. by Panchanan Maiti (1459852)

rhMG53 decreases membrane damage <i>in vitro</i>. by Brian J. Paleo (8694246)